These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24671571)

  • 1. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
    Wang X; Wang ZF; Xie YM; Zhang W; Liao X; Chang YP;
    Chin J Integr Med; 2015 Jun; 21(6):473-80. PubMed ID: 24671571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine].
    Wang X; Su X; Sun W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2844-7. PubMed ID: 22292381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Quality Evaluation of Pharmacoeconomic Studies on Traditional Chinese Medicines.
    Yang N; Zhang H; Deng T; Guo JJ; Hu M
    Front Public Health; 2021; 9():706366. PubMed ID: 34414159
    [No Abstract]   [Full Text] [Related]  

  • 6. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.
    Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ
    Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current state and challenges of pharmacoeconomic evaluation in Korea].
    Choi SE
    J Prev Med Public Health; 2008 Mar; 41(2):74-9. PubMed ID: 18385546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.
    Robertson J; Lang D; Hill S
    J Clin Pharm Ther; 2003 Feb; 28(1):73-9. PubMed ID: 12605622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative review of the pharmacoeconomic guidelines in South Africa.
    Carapinha JL
    J Med Econ; 2017 Jan; 20(1):37-44. PubMed ID: 27564849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature.
    Sanchez LA
    Am J Health Syst Pharm; 1999 Aug; 56(16):1630-8; quiz 1638-40. PubMed ID: 10459385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines for economic evaluation of pharmaceuticals in Korea].
    Bae EY
    J Prev Med Public Health; 2008 Mar; 41(2):80-3. PubMed ID: 18385547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to improve pharmacoeconomic data generalisability between different countries.
    Li SC
    Expert Opin Pharmacother; 2007 Jul; 8(10):1409-13. PubMed ID: 17661723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
    Liao X; Xie YM; Robinson N; Wang YY
    Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overview of pharmacoeconomic studies on traditional Chinese medicines and western medicines in treatment of stroke].
    Chang YP; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Dec; 37(23):3509-12. PubMed ID: 23477129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.